Huei-Ju Ting, Ph.D.
Affiliations: | 2002 | University of Rochester, Rochester, NY |
Area:
Molecular Biology, OncologyGoogle:
"Huei-Ju Ting"Mean distance: 10177.7
Parents
Sign in to add mentorChawnshang Chang | grad student | 2002 | Rochester | |
(The cloning and characterization of androgen receptor coregulators, supervillin and gelsolin.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Hu YC, Yeh S, Yeh SD, et al. (2020) Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382 |
Hu YC, Yeh S, Yeh SD, et al. (2020) Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382 |
Altuwaijri S, Lee DK, Chuang KH, et al. (2020) Correction to: Androgen receptor regulates expression of skeletal muscle-specific proteins and muscle cell types. Endocrine |
Lai GR, Lee YF, Yan SJ, et al. (2020) Active vitamin D induced gene-specific hypomethylation in prostate cancer cells developing vitamin D resistance. American Journal of Physiology. Cell Physiology |
Lin VC, Huang SP, Ting HJ, et al. (2017) Vitamin D receptor-binding site variants affect prostate cancer progression. Oncotarget. 8: 74119-74128 |
Hsu CL, Liu JS, Lin TW, et al. (2017) Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget. 8: 69508-69519 |
Lin VC, Huang SP, Ting HJ, et al. (2017) Vitamin D receptor-binding site variants affect prostate cancer progression. Oncotarget |
Hsu CL, Liu JS, Lin TW, et al. (2017) Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget |
Hsu CL, Liu JS, Wu PL, et al. (2014) Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis. Molecular Oncology. 8: 1575-87 |
Beckham CJ, Olsen J, Yin PN, et al. (2014) Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. The Journal of Urology. 192: 583-92 |